Medicare Draft LCD Proposes Coverage for Pacific Edge's Cxbladder Tests

• Medicare draft LCD covers hematuria evaluation for first time
• Exclusive reimbursement proposed for Cxbladder Triage and Triage Plus
• Triage Plus priced at US$1,328 per test, improving economics
• Draft LCD could influence 223 million US commercial lives
• NZ$31.4 million capital raise underway to support growth

Medicare Draft LCD Opens Reimbursement Door for Urine Biomarkers

Pacific Edge (NZX/ASX:PEB) has taken a significant step toward commercialising its bladder cancer diagnostics in the US with the publication of a draft Local Coverage Determination (LCD) by Medicare. This draft policy, for the first time, proposes coverage for hematuria evaluation using urine-based biomarkers, explicitly naming Pacific Edge's flagship tests, Cxbladder Triage and Triage Plus, as reimbursable. The move could unlock Medicare reimbursement for over 66 million beneficiaries, a potential game-changer for the company’s US market presence.

The draft LCD titled ‘Urine-based Biomarkers in Patients with Microhematuria’ (DL40378) distinguishes microhematuria patients from those with confirmed or suspected cancer, who fall under a separate non-coverage policy. This differentiation is critical because it positions Pacific Edge’s tests as the only urine-based biomarkers eligible for coverage in this patient group. The associated Local Coverage Article (LCA) reinforces this exclusivity by listing only Cxbladder Triage (0363U) and Triage Plus (0420U) for billing and coding guidance, effectively creating a protective moat around Pacific Edge’s microhematuria business.

Novitas, the Medicare Administrative Contractor overseeing Pacific Edge’s Pennsylvania laboratory, justified the draft coverage by citing the low malignancy prevalence in microhematuria patients and the limited diagnostic performance of older urine cytology and biomarkers. It acknowledged the emerging evidence supporting multi-analyte rule-out assays like Cxbladder to aid risk stratification and potentially defer invasive cystoscopy procedures.

Triage Plus Could Shift Pacific Edge’s Profitability Trajectory

Pacific Edge Chief Executive Dr Peter Meintjes highlighted that the inclusion of Triage Plus in the draft LCD is particularly significant. This test offers higher clinical utility across a broader patient base and carries a Medicare reimbursement price of US$1,328 per test, 75% higher than the legacy Cxbladder products priced at US$760. This pricing shift could materially improve Pacific Edge’s operating margins and accelerate its path to profitability in the US market.

Dr Meintjes also noted that the draft LCD aligns closely with American Urological Association guidelines and reflects the clinical evidence Pacific Edge has built over recent years. The company views this as a validation of its evidence-driven strategy, which focuses on generating robust clinical data to influence medical policy and physician behaviour.

Given the draft status, Novitas will enter a minimum 45-day public comment period, including a public meeting to gather feedback. A final decision is expected within 12 months, with coverage becoming effective 45 days after finalisation. Pacific Edge plans to engage actively during this period and seek reimbursement on a claim-by-claim basis for Triage and Triage Plus, anticipating positive momentum.

Capital Raise Supports Medicare Re-Coverage Push

This regulatory milestone coincides with Pacific Edge’s ongoing capital raising efforts. The company recently completed a NZ$25.4 million placement priced at NZ$0.17 per share, primarily subscribed by existing shareholders, and opened a NZ$6 million retail offer for eligible New Zealand investors. These funds are earmarked to bolster operations and support the Medicare re-coverage process, which has been a major focus following the loss of coverage that halved the company’s FY26 revenue to NZ$11.5 million. The retail offer allows shareholders to apply for up to NZ$50,000 of new shares at the same price as the placement, reflecting strong investor confidence in the company’s strategic direction. This funding push follows Pacific Edge’s earlier NZ$24 million capital raise aimed at shoring up finances amid Medicare uncertainty, underscoring the critical nature of the policy outcome for the company’s growth trajectory.

Pacific Edge’s Cxbladder tests have already been adopted by over 5,000 US urologists with more than 130,000 tests ordered, and the company expects Medicare coverage to accelerate uptake further. The draft LCD’s influence could also extend beyond Medicare, providing a framework for commercial insurers covering 223 million US lives and potentially boosting international adoption.

While the draft LCD marks a pivotal moment, the final policy outcome remains uncertain. The public comment period and subsequent Novitas review could lead to modifications or delays. Nonetheless, this development places Pacific Edge in a strong position to capitalise on growing demand for non-invasive bladder cancer diagnostics and to leverage its evidence-based approach to expand market share.

Pacific Edge’s journey highlights the complex interplay between clinical innovation, regulatory policy, and capital markets in shaping the future of cancer diagnostics. The company’s next moves during the LCD finalisation and capital raise subscription periods will be critical to watch as it seeks to convert regulatory progress into commercial success.

NZ$6 million retail offer and NZ$25.4 million placement underpin Pacific Edge’s Medicare re-coverage push, reflecting investor backing amid regulatory uncertainty.

Bottom Line?

Pacific Edge stands at a regulatory and commercial inflection point, but final Medicare coverage and market uptake remain to be seen.

Questions in the middle?

• Will the final Medicare LCD fully endorse Cxbladder Triage Plus reimbursement?
• How quickly will commercial insurers follow Medicare’s lead on urine biomarker coverage?
• Can Pacific Edge convert regulatory progress into sustainable US market profitability?